3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
8
Uveal Melanoma
3
Multiple Myeloma
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Eye Neoplasms
1
Interventions
Vincristine
12
Temozolomide
11
Irinotecan
10
Cyclophosphamide
10
Melphalan
8
Filgrastim
8
Etoposide
7
Ifosfamide
6
Granulocyte Colony-Stimulating Factor
6
Doxorubicin
6
Vinorelbine
5
Gemcitabine
5
Busulfan
5
Thiotepa
4
Radiotherapy
4
Peripheral Blood Stem Cell Transplantation
4
Dactinomycin
4
pegfilgrastim
3
liposomal doxorubicin
3
irinotecan sucrosofate
3
fludarabine
3
etoposide phosphate
3
Stem Cell Transplantation
3
Sirolimus
3
Proton Therapy
3
Cisplatin
3
Carboplatin
3
Bone Marrow Transplantation
3
thymoglobulin
2
regorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rhabdomyosarcoma
×
MAGEA3 protein, human
×
Clear all
NCT00944580
2017-11-24
A Vaccine Study for High Risk Cancers
Penn State University
Phase 1
Withdrawn